Cargando…

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma

In recent years, immune checkpoint blockades (ICBs) have made great progress in the treatment of cancer. However, most ICBs have not yet been observed to be satisfactory in the treatment of osteosarcoma. Herein, we designed composite nanoparticles (NP–Pt-IDOi) from a reactive oxygen species (ROS) se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Dongquan, Han, Xinli, Li, Jianxiong, Zhang, Jiabing, Xiao, Haihua, Li, Ting, Zhao, Xuelin, Xiong, Hejian, Xu, Meng, Bi, Wenzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Full Length Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250924/ https://www.ncbi.nlm.nih.gov/pubmed/37304579 http://dx.doi.org/10.1016/j.mtbio.2023.100675

Ejemplares similares

Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy
por: Ma, Xiao, et al.
Publicado: (2023)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
por: Zacharioudakis, Emmanouil, et al.
Publicado: (2023)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Cell-permeable lanthanide–platinum(iv) anti-cancer prodrugs
por: Yao, Kezi, et al.
Publicado: (2021)

pH/redox sensitive nanoparticles with platinum(iv) prodrugs and doxorubicin enhance chemotherapy in ovarian cancer
por: Zhang, Guyu, et al.
Publicado: (2019)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs
por: Wong, Daniel Yuan Qiang, et al.
Publicado: (2015)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
por: Aputen, Angelico D., et al.
Publicado: (2023)

Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cells
por: Zhu, Zhenzhu, et al.
Publicado: (2016)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells
por: Khoury, Aleen, et al.
Publicado: (2022)

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
por: Zhang, Rongrong, et al.
Publicado: (2017)

Encapsulation of Platinum Prodrugs into PC7A Polymeric Nanoparticles Combined with Immune Checkpoint Inhibitors for Therapeutically Enhanced Multimodal Chemotherapy and Immunotherapy by Activation of the STING Pathway
por: Gao, Xiangjie, et al.
Publicado: (2022)

Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions
por: Savino, Salvatore, et al.
Publicado: (2018)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment
por: Liao, Song, et al.
Publicado: (2023)

Disulfide-containing polymer delivery of C527 and a Platinum(IV) prodrug selectively inhibited protein ubiquitination and tumor growth on cisplatin resistant and patient-derived liver cancer models
por: Shang, Kun, et al.
Publicado: (2023)

Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand
por: Liu, Fengfan, et al.
Publicado: (2019)

Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
por: Barth, Marie-Christin, et al.
Publicado: (2023)

In situ oxidative polymerization of platinum(iv) prodrugs in pore-confined spaces of CaCO(3) nanoparticles for cancer chemoimmunotherapy
por: Wei, Fangmian, et al.
Publicado: (2023)

An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy
por: Liu, Gongyuan, et al.
Publicado: (2023)

Nanoparticle encapsulated CQ/TAM combination harmonizes with MSCs in arresting progression of severity in AP mice through iNOS (IDO) signaling
por: Liu, Huimin, et al.
Publicado: (2022)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance
por: Papadia, Paride, et al.
Publicado: (2020)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug
por: Yang, Bingxue, et al.
Publicado: (2022)

Astragaloside IV Inhibits the Proliferation of Human Uterine Leiomyomas by Targeting IDO1
por: Qiu, Tiantian, et al.
Publicado: (2022)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

Cetuximab-decorated and NIR-activated Nanoparticles Based on Platinum(IV)-prodrug: Preparation, Characterization and In-vitro Anticancer Activity in Epidermoid Carcinoma Cells
por: Wang, Yu, et al.
Publicado: (2021)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Engineering Prodrug Nanomedicine for Cancer Immunotherapy
por: Yang, Bin, et al.
Publicado: (2020)

Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
por: Li, Xuejiao, et al.
Publicado: (2018)

Tolerogenic Splenic IDO(+) Dendritic Cells from the Mice Treated with Induced-Treg Cells Suppress Collagen-Induced Arthritis
por: Yang, Jie, et al.
Publicado: (2014)

Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy
por: Jiang, Wei, et al.
Publicado: (2022)

Editorial: The role of platinum-based antitumor prodrugs in medicinal inorganic chemistry
por: Margiotta, Nicola, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3o1c8rnufcftol5junv00559k